Clinical trials: sponsored by AstraZeneca
Anxiety
Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325
The study is carried out in order to determine the relationship between the dose of AZD7325 and the blood concentration of AZD7325, and to investigate to which extent AZD7325 binds to the GABAA receptors.
- Trial name
- PET (NCT00681720)
- Testing
- AZD7325, Radioligand (11C) flumazenil
- Where
- Sweden
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pain
Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704
The primary aim for this study is to investigate the safety and tolerability of the AZD1704, first time in man.
- Trial name
- NCT00692042
- Testing
- AZD1704
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Capsaicin Evoked Pain, Heat Sensitivity
Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)
A double-blind, randomized, single-centre, placebo-controlled, crossover study to investigate the effects of a single oral dose of AZD1386 on intradermal capsaicin evoked pain symptoms and heat sensitivity in healthy volunteers
- Trial name
- NCT00692146
- Testing
- AZD1386
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Antiplatelet Effect
Study to Investigate Safety and Tolerability of a Single Dose of AZD6482
AZD6482 is a new drug substance aiming to prevent blood clots which may arise in atherosclerotic blood vessels and cause myocardial infarction or stroke. This is the first study with AZD6482 in humans.
- Trial name
- NCT00688714
- Testing
- AZD6482
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- AstraZeneca